- Home
- PRKS vs KARD Comparison
PRKS vs KARD Comparison
Compare PRKS & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRKS | KARD |
|---|---|---|
| Founded | 1959 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2012 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PRKS | KARD |
|---|---|---|
| Price | $42.38 | $20.10 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $47.50 | N/A |
| AVG Volume (30 Days) | ★ 614.7K | 215.1K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $1,263,324,000.00 | N/A |
| Revenue This Year | $3.45 | N/A |
| Revenue Next Year | $3.08 | N/A |
| P/E Ratio | $70.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.77 | $19.58 |
| 52 Week High | $56.95 | $27.00 |
Technical Indicators
Market Signals| Indicator | PRKS | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 45.82 |
| Support Level | $33.47 | $19.67 |
| Resistance Level | $49.08 | $23.02 |
| Average True Range (ATR) | 1.27 | 1.40 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 11.03 | 23.97 |
Price Performance
Historical ComparisonAbout PRKS United Parks & Resorts Inc.
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.